Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In patients with type 2 diabetes and an ICD or CRT-D, ...

The advantage of empagliflozin, and the sodium glucose cotransporter 2 class generally, is that its unique mechanism expels excess glucose through the urine, thus offering the possibility of reducing ...

The EMPA-REG OUTCOME trial is part of the new wave of cardiovascular (CV) outcome trials required by the US Food and Drug Administration (FDA) for all new diabetes drugs. Empagliflozin is in the ...

Please provide your email address to receive an email when new articles are posted on . The benefits of empagliflozin compared with placebo for HF with reduced ejection fraction occurred regardless of ...

EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead ...

Among 34,239 matched pairs, the risk of incident nonproliferative diabetic retinopathy was not different between patients taking empagliflozin or DPP-4 inhibitors (HR 1.04, 95% CI 0.94-1.15) over a ...

The EMPEROR-Preserved trial of empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) met its primary endpoint, according to top-line results released today, meaning a therapy with specific ...

The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high ...

An investigation led by Brigham and Women's Hospital finds empagliflozin (sold as Jardiance) may reduce the risk of diabetic ...